Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in J Crohns Colitis

Retrieve available abstracts of 282 articles:
HTML format
Text format



Single Articles


    September 2017
  1. SHI HY, Chan FKL, Chan AWH, Higashimori A, et al
    Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores.
    J Crohns Colitis. 2017;11:1071-1077.
    PubMed     Text format     Abstract available


    August 2017
  2. TURNER D, Carle A, Steiner SJ, Margolis PA, et al
    Quality Items Required for Running a Paediatric Inflammatory Bowel Disease Centre: An ECCO Paper.
    J Crohns Colitis. 2017;11:981-987.
    PubMed     Text format     Abstract available


    June 2017
  3. ABREU C, Afonso J, Dias CC, Ruas R, et al
    Serial Tuberculosis screening in inflammatory bowel disease patients under anti-TNFalpha therapy.
    J Crohns Colitis. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. LEDDER O, Assa A, Levine A, Escher JC, et al
    Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN.
    J Crohns Colitis. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  5. BURISCH J, Vegh Z, Katsanos KH, Christodoulou DK, et al
    Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort - An ECCO-EpiCom study.
    J Crohns Colitis. 2017 May 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. ANIWAN S, Loftus EV Jr
    Bringing the Mucosa to Heal with Vedolizumab in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 May 27. doi: 10.1093.
    PubMed     Text format    


  7. STREMMEL W, Staffer S, Schneider MJ, Gan-Schreier H, et al
    Genetic mouse models with intestinal-specific tight junction deletion resemble an ulcerative colitis phenotype.
    J Crohns Colitis. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. GASPAR R, Liberal R, Macedo G
    Mucosal healing in ulcerative colitis patients treated with vedolizumab: patient-, dose- or duration-dependant?
    J Crohns Colitis. 2017 May 22. doi: 10.1093.
    PubMed     Text format    


  9. CARBONNEL F, Boutron MC
    Incidence, phenotype and mortality of inflammatory bowel disease twenty years after.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed     Text format    


  10. COX SR, Prince AC, Myers CE, Irving PM, et al
    Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. KAROLEWSKA-BOCHENEK K, Dziekiewicz M, Banaszkiewicz A
    Budesonide MMX in pediatric patients with ulcerative colitis.
    J Crohns Colitis. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  12. PARAMSOTHY S, Paramsothy R, Rubin DT, Kamm MA, et al
    Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. NIKOLAUS S, Schreiber S, Siegmund B, Bokemeyer B, et al
    Patient education in a 14 month randomized trial fails to improve adherence in ulcerative colitis: Influence of demographic and clinical parameters on non-adherence.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. BURISCH J, Ungaro R, Vind I, Prosberg MV, et al
    Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. HORJUS TALABUR HORJE CS
    AlfaEbeta7 integrin expression on T cells in Ulcerative Colitis.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format    


  16. MACMANUS CF, Collins CB, Nguyen TT, Alfano RW, et al
    VEN-120, a recombinant human lactoferrin, promotes a regulatory T cell (Treg) phenotype and drives resolution of inflammation in distinct murine models of inflammatory bowel disease.
    J Crohns Colitis. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. KOTZE PG, Yamamoto T
    Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?
    J Crohns Colitis. 2017;11:643.
    PubMed     Text format    


  18. LAMB CA, Mansfield JC, Tew GW, Gibbons D, et al
    alphaEbeta7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:610-620.
    PubMed     Text format     Abstract available


  19. CHU TPC, Moran GW, Card TR
    The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study.
    J Crohns Colitis. 2017;11:578-585.
    PubMed     Text format     Abstract available


  20. LIM KJ, Lee SJ, Kim S, Lee SY, et al
    Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:593-602.
    PubMed     Text format     Abstract available


  21. LIGHTNER AL, Loftus EV
    Response to 'Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?'
    J Crohns Colitis. 2017;11:644-645.
    PubMed     Text format    


  22. MELESSE DY, Lix LM, Nugent Z, Targownik LE, et al
    Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study.
    J Crohns Colitis. 2017;11:562-570.
    PubMed     Text format     Abstract available


  23. KARREMAN MC, Luime JJ, Hazes JMW, Weel AEAM, et al
    The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017;11:631-642.
    PubMed     Text format     Abstract available


  24. EBERHARDSON M, Karlen P, Linton L, Jones P, et al
    Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
    J Crohns Colitis. 2017;11:534-542.
    PubMed     Text format     Abstract available


  25. DAPERNO M, Comberlato M, Bossa F, Armuzzi A, et al
    Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.
    J Crohns Colitis. 2017;11:556-561.
    PubMed     Text format     Abstract available


  26. BEQUET E, Sarter H, Fumery M, Vasseur F, et al
    Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
    J Crohns Colitis. 2017;11:519-526.
    PubMed     Text format     Abstract available


  27. HOVDE O, Hoivik ML, Henriksen M, Solberg IC, et al
    Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study.
    J Crohns Colitis. 2017;11:571-577.
    PubMed     Text format     Abstract available


  28. TURNER D, Yerushalmi B, Kori M, Broide E, et al
    Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
    J Crohns Colitis. 2017;11:527-533.
    PubMed     Text format     Abstract available


    April 2017
  29. HARKIN G, Keogh A, Slattery E
    The Effect of Biosimilars (Inflectra(R),) in the management of Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  30. GWELA A, Siddhanathi P, Chapman RW, Travis S, et al
    Th1 and Innate Lymphoid Cells accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Apr 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  31. WISNIEWSKI A, Flejou JF, Siproudhis L, Abramowitz L, et al
    Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives.
    J Crohns Colitis. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. NOMAN M, Ferrante M, Bisschops R, De Hertogh G, et al
    Vedolizumab induces long term mucosal healing in patients with Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. LEVINE A, Yerushalmi B, Kori M, Broide E, et al
    Mesalamine enemas for induction of remission in oral mesalamine refractory pediatric ulcerative colitis: a prospective cohort study.
    J Crohns Colitis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. COTON C, Maggiori L, Mege D, Naudot C, et al
    Ileal pouch-anal anastomosis for dysplasia or cancer complicating inflammatory bowel disease: Is total mesorectal excision always mandatory? an analysis of 36 consecutive patients.
    J Crohns Colitis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. REBOREDO MM, Pinheiro BV, Chebli JM
    Physical exercise programs in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format    


  36. CANTORO L, Di Sabatino A, Papi C, Margagnoni G, et al
    The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: an Italian multicentre study.
    J Crohns Colitis. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. JUNG YS, Han M, Kim WH, Park S, et al
    Cancer risk in the Early Stages of Inflammatory Bowel Disease in Korean patients: A Nationwide Population-based Study.
    J Crohns Colitis. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. MOHAMMED K, Shaik NA, Al-Abbasi FA
    Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease: A Correction.
    J Crohns Colitis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  39. WISNIEWSKI A, Flejou JF, Siproudhis L, Abramowitz L, et al
    Anal neoplasia in Inflammatory Bowel Disease: Classification proposal, epidemiology, carcinogenesis and risk management perspectives.
    J Crohns Colitis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available



  40. Corrigendum: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format    



  41. Erratum: Use of digital technology to boost patient recruitment in inflammatory bowel disease clinical trials.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format    


  42. RUBIN DT, Cohen RD, Sandborn WJ, Lichtenstein GR, et al
    Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.
    J Crohns Colitis. 2017 Mar 4. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  43. LEE HS, Oh H, Baek J, Jung S, et al
    X chromosome-wide association study identifies a susceptibility locus for inflammatory bowel disease in Koreans.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. UCHIYAMA K, Takagi T, Kashiwagi S, Toyokawa Y, et al
    Assessment of endoscopic mucosal healing of ulcerative colitis using linked colour imaging, a novel endoscopic enhancement system.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. DANESE S, Bonovas S, Peyrin-Biroulet L
    Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format    


  46. UZZAN M, Kirchgesner J, Oubaya N, Amiot A, et al
    Risk of rectal neoplasia after colectomy and ileorectal anastomosis for ulcerative colitis.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. ROSARIO M, French JL, Dirks NL, Sankoh S, et al
    Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. RUIZ DE MORALES JG, Munoz F, Hernando M
    Successful treatment of Common Variable Immunodeficiency-associated inflammatory bowel disease with Ustekinumab.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format    


  49. TAXONERA C, Ponferrada A, Bermejo F, Riestra S, et al
    Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. LYKOURAS D, Karkoulias K, Triantos C
    Physical Exercise in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 10. doi: 10.1093.
    PubMed     Text format    


  51. MAGRO F, Gionchetti P, Eliakim R, Ardizzone S, et al
    Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed     Text format    


  52. VAN RHEENEN PF, Aloi M, Biron IA, Carlsen K, et al
    European Crohn's and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed     Text format    


  53. DE VRIES L, Wildenberg M, de Jonge W, D'Haens G, et al
    The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed     Text format    


  54. ONIDI FM, Mocci G, Cabras F
    N814 Improvement in the treatment and management of patients affected by inflammatory bowel disease: hepatitis B and vaccination status.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  55. SHAH SC, Khalili H, Gower-Rousseau C, Olen O, et al
    P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  56. SILVA RP, Bissoli GC, Farinelli E, Sibia CF, et al
    N811 Infliximab versus adalimumab: clinical and endoscopy response in ulcerative colitis patients. A prospective study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  57. MANCENIDO MARCOS N, Pajares Villarroya R, Salinas Moreno S, Arribas Lomicronpez MR, et al
    P697 Association of inflammatory bowel disease and celiac disease. Experience in a hospital of the autonomous community of Madrid (Spain).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  58. HIRANO A, Umeno J, Shibata H, Kitazono T, et al
    P784 A comparison study of the mucosa-associated microbiota between inflamed and non-inflamed sites in ulcerative colitis patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  59. PONCE-ALONSO M, Garcia-Fernandez S, Aguilera L, Rodriguez-de-Santiago E, et al
    P782 A new compatibility test for donor selection for faecal microbiota transplantation in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  60. BASTON I, Sueiro R, Uribarri L, Ferreiro R, et al
    P785 Association of Bacteroidetes with endoscopic activity in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  61. RICANEK P, Rahul K, Ber Y, Vatn S, et al
    P788 Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  62. RIVERA SEQUEIROS A, Gil Garcia E, Chillomicronn Martinez R
    N800 Statistical comparison of predictors of quality of life in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  63. SLADEK M, Vultaggio A, Ghione S, Nencini F, et al
    P661 Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade(R)) in children with established inflammatory bowel disease: a multi-centre prospective observational s
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  64. HELLSTROM PM, Stalhammar J, Beydogan H, Huetson P, et al
    P735 Indirect burden of patients with moderate inflammatory bowel disease in Uppsala County Council, Sweden: a retrospective study using real-world data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  65. ISHIKAWA D, Takahashi M, Haga K, Shibuya T, et al
    P766 Combination therapy of fresh fecal microbial transplantation and antibiotics for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  66. DING NS, Yazdanian B, Bettenworth D, Cleynen I, et al
    P738 Assessing aCCess to investigations in IBD (ACCID) - results from an international inflammatory bowel disease survey.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  67. FONSECA CAMARILLO G, Iturriaga Goyon E, Yamamoto Furusho JK
    P765 Transcriptome of intestinal epithelial barrier genes in the colonic mucosa from patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  68. BORREN N, Tan W, Andrews E, Khalili H, et al
    P704 The impact of travel distance on disease outcomes in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  69. SIBIA CF, Silva RP, Ariede JR, Severino FE, et al
    P760 microRNA expression profiling of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  70. JELAKOVIC M, Brinar M, Turk N, Prijic R, et al
    P747 Extracolonic and colonic cancer risk in patients with ulcerative colitis and primary sclerosing cholangitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  71. FRAGAKI M, Bachlitzanaki M, Karmiris K, Theodoropoulou A, et al
    P709 inflammatory bowel disease and colorectal cancer: analysis of a single center retrospective chart review.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  72. CROWLEY E, Elkadri A, Warner N, Zhang S, et al
    P754 X-linked inhibitor of apoptosis protein genetic variants in paediatric-onset inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  73. FONSECA CAMARILLO G, Iturriaga Goyon E, Yamamoto Furusho JK
    P762 Gene expression profiling of immune adaptive response in the colonic mucosa from patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  74. DIBLEY L, Williams E, Young P, Ironside P, et al
    N798 Kinship stigma in community-dwelling people with inflammatory bowel disease: family acknowledgement matters.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  75. RASMUSSEN M, Brynskov J, Ainsworth MA, Buhl S, et al
    P584 A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  76. GOMPERTZ M, Alfaro I, Ricart E, Lomicronpez A, et al
    P679 Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  77. FIORINO G, Ruiz-Aguello MB, Maguregui A, Nagore D, et al
    P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  78. GARCIA ORTIZ JM, Saenz Gallo M, Trigo Salado C, De La Cruz Ramirez MD, et al
    P634 Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  79. SANDBORN W, Sakuraba A, Wang A, Macaulay D, et al
    P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  80. MOLNAR T, Farkas K, Rutka M, Ferenci T, et al
    P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis - 54 week data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  81. CHAO CY, Lemieux C, Afif W, Bitton A, et al
    P677 Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  82. RODRIGUEZ GLEZ GE, Diaz Hernandez L, Morales Barrios JA, Vela Gonzalez M, et al
    P629 Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  83. DE VILLE DE GOYET L, Moreels T, Denis MA, De Vroey B, et al
    P732 Clinical characteristics of inflammatory bowel disease in Belgian immigrants from Moroccan and Caucasian origin.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  84. ROSEIRA J, Tavares de Sousa H, Marreiros A, Estevens D, et al
    P723 SexIDI study - sexual satisfaction in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  85. MYRELID P, Landerholm K, Nordenvall C, Pinkney TD, et al
    P724 Appendectomy is not a treatment option for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  86. DERWA Y, Gracie DJ, Williams CJ, Sood R, et al
    P655 A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  87. RIVIERE P, Laharie D, Zerbib F, Poullenot F, et al
    P680 Quality of sex life in patients with inflammatory bowel disease: the gastroenterologists' perspective.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  88. MCGOWAN M, Kokkorou M, Rebull M, Koh Y, et al
    P587 Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controls.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  89. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    P620 Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  90. HUGUET M, Pereira B, Goutte M, Goutorbe F, et al
    P628 Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  91. PENA-SANCHEZ JN, Lix LM, Teare GF, Li W, et al
    P725 The impact of an integrated model of care for patients with inflammatory bowel disease in Canada.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  92. EL-MATARY W, Deora V
    P651 Barriers to clinical research in children with inflammatory bowel disease: the patients' perspective.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  93. SUTTON R, Wierstra K, Ambrosio L, Dieleman L, et al
    P552 An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medication.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  94. SCHREIBER S, Dignass A, Peyrin-Biroulet L, Hather G, et al
    P466 Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  95. KIM KO, Jang BI, Koo EJ, Kang MK, et al
    P657 The predictors and clinical outcomes of follow up loss of clinics in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  96. KOO JS, Kim DJ, Lee DW, Jeen YJ, et al
    P604 Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  97. FIORINO G, Ametzazurra A, Nagore D, Hernandez AM, et al
    P605 Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  98. TANAKA T, Goishi H, Kajihara T, Akagi M, et al
    P518 Remission induction in corticosteroid naive children and adolescents with ulcerative colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  99. YLISAUKKO-OJA T, Eberl A, Aaltonen J, Nuutinen H, et al
    P515 Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  100. RASMUSSEN M, Brynskov J, Ainsworth MA, Buhl S, et al
    P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  101. YAMAMOTO T, Tanaka T, Yokoyama T, Shimoyama T, et al
    P540 Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  102. KANG B, Lee K, Choe YH
    P542 Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset inflammatory bowel disease patients: a single centre prospective observational study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  103. LITTLE R, Taylor K, Friedman A, Headon B, et al
    P609 A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  104. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    P555 Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  105. SAIBENI S, Bezzio C, Armuzzi A, Bossa F, et al
    P652 Unmet needs of physicians managing inflammatory bowel disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  106. GREWAL CS, Sood A, Mehta V, Kaur D, et al
    P596 FMT in patients with steroid dependant ulcerative colitis a single centre observational study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  107. NARULA N, Borges L, Steinhart AH, Colombel JF, et al
    P415 Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  108. YOKOYAMA K, Kawagishi K, Kobayashi K, Koizumi W, et al
    P570 Current status of the effectiveness of infliximab in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  109. MANOSA M, Corrales G, Olivares D, Vicuna M, et al
    P480 Characteristics of drug-induced lupus 2 degrees to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  110. GULATI S, Emmanuel A, Burt M, Hayee B, et al
    P535 Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  111. WALJEE A, Liu B, Sauder K, Zhu J, et al
    P361 Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  112. PROTIC M, Seibold F, Manser C, Frei P, et al
    P569 Sequential rescue treatments in steroid refractory ulcerative colitis: two-year follow-up.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  113. KOLAR M, Duricova D, Bortlik M, Hruba V, et al
    P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients - one-year clinical follow-up.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  114. SPIZZO P
    P556 Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabled.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  115. BRYANT R, Costello S, Schoeman S, Sathananthan D, et al
    P577 "Treat to target" recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  116. YE L, Liu J, Lin Z, Cao Q, et al
    P568 Does infliximab therapy increase incidence of tuberculosis in patients with inflammatory bowel disease in an endemic area: a nationwide study from China.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  117. LOBATON T, Canete F, Teniente A, Cabre E, et al
    P562 Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  118. AMETZAZURRA A, Rivera N, Hernandez AM, Arreba MP, et al
    P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  119. YADAV A, Forry M, O'Toole A, Patchett S, et al
    P520 Perspective and self-efficacy of adolescents with inflammatory bowel disease post transition to adult care.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  120. BERNARDO S, Fernandes S, Goncalves AR, Baldaia C, et al
    P453 Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  121. ESTEVEZ-GIL M, De Castro ML, Hernandez V, Pineda JR, et al
    P455 Clinical features of tuberculosis infection in inflammatory bowel disease patients on anti-TNF therapy.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  122. CARMAN N, Huynh H, Walsh CM, Ricciuto A, et al
    P450 Reliability assessment of endoscopic scoring tools using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  123. PITUCH-ZDANOWSKA A, Stawicka A, Jarocka-Cyrta E, Banaszkiewicz A, et al
    P346 Dietary practices and beliefs among parents of children with inflammatory bowel disease: preliminary results.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  124. HAZEL K, Forry M, Patchett S, O'Toole A, et al
    P371 Healthcare maintenance in inflammatory bowel disease patients: need for a top down approach.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  125. SAIBENI S, Bezzio C, Armuzzi A, Bossa F, et al
    P574 Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  126. HEIDA A, Knol M, Muller Kobold A, Dijkstra G, et al
    P374 Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  127. SOUSA P, Martins D, Pinho J, Cancela E, et al
    P284 Ulcerative colitis - presentation during pregnancy or puerperium.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  128. AL KHOURY A, Chao CY, Aruljothy A, Wyse J, et al
    P495 Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  129. BALABAN DV, Popp A, Robu G, Bucurica S, et al
    P323 Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  130. MELLOTTE G, McShane C, O'Connell J, Mc Kiernan S, et al
    P491 Comparison of the durability of response to subcutaneous anti-TNF therapy between ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  131. FUH F, Tew W, Keir M, Looney C, et al
    P431 Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab dose.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  132. PUGLIESE D, Armuzzi A, Panici Tonucci T, Tolusso B, et al
    P440 Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  133. SIECZKOWSKA-GOLUB J, Jarzebicka D, Borys-Iwanicka A, Korlatowicz-Bilar A, et al
    P504 Differences between paediatric and adult inflammatory bowel disease presentation - analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy - Satimos study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  134. TRAVIS S, Feagan B, Peyrin-Biroulet L, Panaccione R, et al
    P329 Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  135. ORLANDINI B, Dragoni G, Bagnoli S, Deiana S, et al
    P407 Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naive patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  136. GHOSH S, Peyrin-Biroulet L, Sensky T, Casellas F, et al
    P359 Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  137. MARSHALL JK, Marrache AM, Ewara E
    P383 Increasing treatment time on REMICADE(R) (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  138. PEREZ-PAMPIN E, Ferreiro R, Lorenzo A, Mera A, et al
    P285 Usefulness of a multidisciplinary approach combining both rheumatology and gastroenterology for the assessment and treatment of inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  139. MULCAHY H, Wynne B, McHugh L, Rowan C, et al
    P370 A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  140. ZAMBORSKY T, Berakova K, Kadleckova B, Podmanicky D, et al
    P339 MadCAM1 expression in intestinal lamina propria endothelium varies among inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  141. PARRA RS, Feitosa MR, Feres O, Rocha JJ, et al
    P424 Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  142. MANTAKA A, Renieri V, Koutroubakis I
    P340 Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  143. KEETARUT K, Bloom S, Qu X, Grimble G, et al
    P376 Assessment of nutritional status and food related experience of adult inflammatory bowel disease inpatients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  144. OGASHIWA T, Nishio M, Otake H, Inoue E, et al
    P337 Efficacy of intravenous cyclosporine in fulminant steroid-refractory ulcerative colitis with massive bleeding: a retrospective, observational study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  145. MORTIER K, Arnott I, Russell RK
    P333 Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  146. GUBATAN JM, Mitsuhashi S, Longhi MS, Zenlea T, et al
    P344 Vitamin D-Induced alterations in Cytokine levels lower the risk of clinical relapse in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  147. YANG HR, Cho JM
    P237 Hair mineral and trace element contents as reliable markers of nutritional status compared to serum levels in children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  148. KIM M
    P399 Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  149. LEVINE A, Yerushalmi B, Kori M, Broide E, et al
    P409 Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  150. COHEN S, Martinez-Vinson C, Aloi M, Turner D, et al
    P302 Cytomegalovirus infection in pediatric acute severe ulcerative colitis - a multicenter case-controlled study from the Pediatric IBD Porto group of ESPGHAN.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  151. COHEN I, Benyamini Y, Tulchinsky H, Dotan I, et al
    P300 Illness perceptions and coping with health-related quality of life in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  152. MEGLICKA M, Szczepanski M, Bierla J, Dadalski M, et al
    P265 Comparison of two faecal calprotectin assays in monitoring children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  153. PITTET V, Maillard MH, Rogler G, Michetti P, et al
    P298 Comparison between clinical and patient-reported symptoms among Crohn's disease and ulcerative colitis patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  154. WILLIET N, Nancey S, Boureille A, Altwegg R, et al
    P310 Development of a new clinico-biological score associated with disease activity in patients with inflammatory bowel disease treated with thiopurine.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  155. GONZALEZ-LOPEZ J, Giraldez-Montero JM, Ferreiro R, Lorenzo A, et al
    P280 Therapeutic drug monitoring of infliximab and adalimumab for detection of patients at risk of loss of response in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  156. MAJOROVA E, Susterova I, Kolarcik P, Fandakova I, et al
    P247 Fungal infections in children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  157. LIMSRIVILAI J, Stidham RW, Govani S, Waljee A, et al
    P303 Gastrointestinal infectious agents detected by Biofire FilmArray GI PCR panel stool testing in active inflammatory bowel disease are common and associated with a more benign course of IBD.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  158. FERREIRA J, Thomas S, Tomer G
    P334 Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  159. YI F
    P286 Evaluation of fecal S100A12 in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  160. BUDZYNSKA A, Nowakowska-Dulawa E, Gawron-Kiszka M, Spiewak J, et al
    P189 Serum neutrophil gelatinase-associated lipocalin correlates with Mayo Clinic score in ulcerative colitis but fails to predict activity in Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  161. LORES T, Goess C, Hrycek C, Grafton R, et al
    P238 Mental health issues and healthcare utilisation in outpatients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  162. ADMYRE C, Zargari A, Atreya R, Knittel T, et al
    P080 IL-10 induction properties of the TLR-9 agonist cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  163. LEE SH, Seo H, Chang K, Song EM, et al
    P148 Fecal calprotectin as a noninvasive indicator for ulcerative colitis disease activity in the Korean cohort.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  164. SMIDS C, Horjus Talabur Horje C, Groenen M, van Koolwijk E, et al
    P313 Glycan antibodies and pANCA in newly diagnosed inflammatory bowel disease patients at presentation and during follow-up.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  165. PAUL S, Duru G, De Vries A, Marini JC, et al
    P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  166. HICKS L, Powles S, Swann J, Chong L, et al
    P182 Assessing the effect of ethnicity on urinary metabolic profiles in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  167. CHAPARRO M, Barreiro-de Acosta M, Echarri A, Almendros R, et al
    P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  168. BOUTALEB A, Saoula H, Aissaoui M, Hamidouche D, et al
    P206 Celiac disease and inflammatory bowel disease, a rare association.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  169. BITTL M, Petersen F, Maaser C, Rath S, et al
    P171 Reliable assessment of ultrasound parameters during transabdominal ultrasonography in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  170. WEI SC, Shih IL, Lin BR, Yen RF, et al
    P199 PET/MR for evaluating subclinical inflammation of ulcerative colitis in remission.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  171. ZHANG W, Teng G, Wang H, Tian Y, et al
    P166 Decreased expression of elafin in peripheral blood and intestinal mucosa in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  172. ZAMBRANO PEREZ A, Shergill-Bonner R, Kiparissi F, Acton N, et al
    P219 Inflammatory bowel disease in children is a challenging diagnosis when overlaps with coeliac disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  173. OHTA Y, Taida T, Nakagawa T, Hamanaka S, et al
    P231 Backgrounds and D-dimer on admission are useful factors for predicting venous thromboembolic complications in hospitalized patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  174. UDUPA V, Baird A, Winter D
    P109 Profiling of receptor for advanced glycation end products expression in cases of primary sclerosing cholangitis with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  175. FONSECA CAMARILLO G, Furuzawa Carballeda J, Iturriaga Goyon E, Yamamoto Furusho JK, et al
    P042 Expression of IL-38 and their antagonists in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  176. LOMICRONPEZ-SERRANO A, Paredes JM, Polanco A, Garcia C, et al
    P224 Virtual chromoendoscopy with i-Scan as alternative to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  177. TEIXEIRA C, Martins C, Ribeiro S, Trabulo D, et al
    P137 Ulcerative colitis in the elderly - Different disease course?
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  178. ZARGARI A, Admyre C, Knittel T
    P106 Binding properties of human TLR-9 receptor to cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  179. CHAO K, Zhu X, Cao Q, Yang H, et al
    P096 Combined detection variants of NUDT15 could highly predict thiopurine-induced leukopenia in Chinese patients with inflammatory bowel disease: a multi-center analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  180. TAIDA T, Nakagawa T, Fujie M, Ohta Y, et al
    P159 Real-time endoscopic-guided measurement of rectal mucosal admittance: a novel and safety method for prediction of relapse in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  181. ROTTOLI M, Vallicelli C, Bigonzi E, Di Simone M, et al
    DOP041 Prepouch ileitis after ileal pouch anal anastomosis for ulcerative colitis: patterns of presentation and risk factors for failure of treatment.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  182. CARMAN N, Huynh H, Mouzaki M, Crowley E, et al
    DOP072 Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  183. ATREYA R, Kuhbacher T, Waldner MJ, Hirschmann S, et al
    DOP073 Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  184. BORREN N, Goel G, Lassen K, Devaney K, et al
    P023 Fatigue in quiescent inflammatory bowel disease is associated with low GM-CSF levels and metabolomic alterations.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  185. VANDE CASTEELE N, Jairath V, Levesque B, Feagan B, et al
    DOP033 Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  186. GAGNIERE C, Bourrier A, Seksik P, Gornet JM, et al
    DOP011 Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  187. COSTELLO S, Waters O, Bryant R, Katsikeros R, et al
    OP036 Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  188. SPEKHORST L, Severs M, de Boer NK, Festen EA, et al
    DOP004 Ethnicity and country of birth are associated with phenotypic differences in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  189. DULAI P, Buckey J, Raffals L, Swoger J, et al
    OP021 Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trial.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  190. BURISCH J, Vind I, Prosberg M, Colombel JF, et al
    DOP003 Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  191. BOTS S, Hoekman D, Benninga M, Ponsioen C, et al
    DOP017 Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  192. IQBAL T, Beggs A, Taniere P, Wallis Y, et al
    OP002 Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  193. SACLEUX SC, Charpentier C, Sarter H, Fumery M, et al
    DOP045 Post-operative complications in elderly-onset inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  194. SANDBORN WJ, Cyrille M, Hansen MB, Feagan BG, et al
    OP034 Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  195. DE FRANCISCO R, Riestra S, Perez-Martinez I, Castano A, et al
    DOP012 Impact on clinical practice of Epstein-Barr virus infection in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  196. SIGALL BONEH R, Levine A, Lomer M, Wierdsma N, et al
    DOP006 Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  197. DE JONG M, van der Meulen-de Jong A, Romberg-Camps M, Becx M, et al
    OP017 Telemedicine enables a safe shift from examination room based care to personalised care for inflammatory bowel disease: a pragmatic randomised multicenter trial with myIBDcoach.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  198. SANDBORN W, Feagan B, D'Haens G, Levesque B, et al
    OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  199. STALLMACH A, Bokemeyer B, Axler J, Curtis R, et al
    DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  200. SELLGE G, Papoutsopoulou S, Verdier J, Trautwein C, et al
    DOP049 Inflammatory dyskinesis: defects of NF-kappaB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  201. MOUTSIANAS L, De Lange K, Luo Y, Lee J, et al
    OP001 Whole genome sequencing and imputation in inflammatory bowel disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  202. FARINELLI E, Pagnin AF, Silva RP, Sibia CF, et al
    N817 Epidemiological profile of Crohn's disease and ulcerative colitis in a Brazilian single centre.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  203. VINAYAGA-PAVAN M, Frampton M, Pontikos N, Levine A, et al
    P758 Elevation in ribosomal and cell cycle gene transcription in macroscopically normal colonic tissue from Icelandic patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  204. OLBJORN C, Cvancarova Smastuen M, Casen C, Nakstad B, et al
    P778 Microbial characterization of paediatric inflammatory bowel disease and stratification into disease severity groups.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  205. GORDILLO J, Torres P, Garcia-Garcia de Paredes A, Llaomicron J, et al
    P706 Caracterization of de novo inflammatory bowel disease (IBD) diagnosed in immigrants migrating from low to high prevalence areas of IBD: a case-control study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  206. BARROS J, Baima J, Renosto F, Sibia C, et al
    NO001 Clinical and psychological factors associated with Erectile Dysfunction in inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  207. SANROMAN ALVAREZ L, Figueira Alvarez M, De Castro Parga ML, Hernandez Ramirez V, et al
    N801 Patient opinion assessment of a comprehensive clinical tool to improve health-care in inflammatory bowel disease. The Implica-2 project.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  208. BRANCO JC, Cardoso M, Anapaz V, Lourenco L, et al
    P714 Vitamin D deficiency in inflammatory bowel disease: prevalence and relation to disease activity in a cohort of patients of a Mediterranean country.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  209. JOHNS K
    N810 Audit of patient satisfaction with telephone reviews for inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  210. SARID O, Slomin-Nevo V, Schwartz D, Friger M, et al
    P749 Impact of psycho-social variables on the activity of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  211. LIM WC, Lin H
    P660 Prevalence and clinical course of cytomegalovirus colitis in Asian patients with acute exacerbation of ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  212. SILVA RP, Baima JP, Bissoli GC, Farinelli E, et al
    N816 Anti-TNF therapy improves the quality of life in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  213. MORREALE GC, Calvaruso V, Sanfratello A, Cappello M, et al
    P658 The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy and quality of life.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  214. VAN DEN HEUVEL T, Bijnens E, Verhaegh B, Nawrot T, et al
    P690 Ambient air quality does not affect disease course in inflammatory bowel disease - a population based risk factor analysis using geographic information systems.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  215. HUH G, Yoon H, Choi YJ, Park YS, et al
    P715 Trends in emergency department visits and hospitalization rates for inflammatory bowel disease: results from a single-center in 2004, 2009 and 2014.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  216. JUZENAS S, Skieceviciene J, Salteniene V, Kupcinskas J, et al
    P759 MiRNA expression patterns in colon of active and inactive ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  217. PERDIGOTO D, Portela F, Ferreira M, Mendes S, et al
    P600 Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  218. WEISSHOF R, Aharoni Golan M, Masching A, Rubin DT, et al
    P619 Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  219. VANCAMELBEKE M, Sabino J, Deroover L, Vandermeulen G, et al
    P774 Metagenomics and metabolomics of patients with inflammatory bowel disease and their unaffected relatives.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  220. PASCHOS P, Katsoula A, Giouleme O, Tsapas A, et al
    P662 Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  221. BROLY F, Fumery M, Vasseur F, Savoye G, et al
    P756 Diagnosing rare inherited disorders using targeted next generation sequencing in patients with early-onset inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  222. JUAN G, Alvarino A, Mora M, Oltra L, et al
    P557 Utility of "trough levels" adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic model.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  223. PEERANI F, Chang H, Ungaro R, Torres J, et al
    P705 Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  224. OPSTELTEN J, Chan S, Hart A, van Schaik F, et al
    P722 Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  225. GOBBO MONTOYA M, Marin-Jimenez I, Panadero A, Modino Y, et al
    P736 Psychological impact of inflammatory bowel disease: differences by gender and age. The ENMENTE Project.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  226. WILLEMZE R, Bakker T, Pippias M, Ponsioen C, et al
    P716 Beta-blocker use is associated with a higher relapse risk of inflammatory bowel disease - a Dutch retrospective cohort study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  227. BURISCH J, Halfvarson J, Kupcinskas L, Hernandez V, et al
    P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  228. WATTS G, Arasaradnam R, Travis S, Sharma A, et al
    P512 Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  229. KAMPERIDIS N, O'Connor M, Crook K, Arebi N, et al
    P490 A pilot study of the electronic patient portal "Patient Knows Best" for monitoring biologic therapy in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  230. YAMAMOTO T, Shimoyama T, Umegae S
    P497 Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  231. RUBIN DT, Panes J, Lindsay JO, Vermeire S, et al
    P558 The SF-36(R) Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  232. GUERRERO PUENTE LN, Iglesias Flores E, Benitez Cantero JM, Cardenas Aranzana MJ, et al
    P545 Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  233. SMITS L, Grelack A, Drenth J, de Jong D, et al
    P663 Switching from Remicade(R) to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  234. HUOPONEN S, Eberl A, Rasanen P, Roine RP, et al
    P685 Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  235. MAKARCHUK P, Belousova E, Volchkova E, Kudriavtseva E, et al
    P517 Features of cytomegalovirus infection in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  236. SAMBUELLI A, Bellicoso M, Negreira S, Goncalves S, et al
    P585 Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategy.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  237. BAKER D, Marshall J, Lee M, Jones G, et al
    P443 Systematic review of internet decision making resources for patients considering surgery for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  238. CHADOKUFA S, Sider S, Huggett B, Sawney T, et al
    P591 Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  239. DE BRUYN M, Ringold R, Ferrante M, Van Assche G, et al
    P382 A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  240. BOSSA F, Valvano MR, Costantino G, Vinci E, et al
    P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  241. CAGOL L, Frivolt K, Krahl A, Forster N, et al
    P486 Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  242. LOPETUSO LR, Petito V, Graziani C, Scannone D, et al
    P498 Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  243. SANDBORN WJ, Rutgeerts P, Zhang H, Adedokun OJ, et al
    P446 Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  244. KANG B, Choi JY, Lee K, Lee SY, et al
    P755 NUDT15 polymorphism is associated with thiopurine-related leukopenia independently of 6-thioguanine nucleotide levels in Korean paediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  245. PANES J, Rubin DT, Vermeire S, Lindsay JO, et al
    P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  246. ORDAS I, Domenech E, Aguas M, Fernandez-Banares F, et al
    P607 Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989-2013): a multicenter nationwide study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  247. BEN-HORIN S, Andrews JM, Katsanos KH, Rieder F, et al
    P341 Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  248. PAUWELS RW, De Vries AC, Van der Woude CJ
    P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  249. BASTIDA G, Sargalt L, Garcia V, Mesonero F, et al
    P528 Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  250. DANESE S, Gisbert JP, Lobo AJ, Dignass A, et al
    P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  251. THI AA, Bouri S, Wolfson P, Owen L, et al
    P439 Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  252. LEFEVRE C, Fotsing G, Wangermez M, Beau P, et al
    P396 Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  253. GIONCHETTI P, Dignass A, Danese S, Magro Dias FJ, et al
    3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.
    J Crohns Colitis. 2017;11:135-149.
    PubMed     Text format     Abstract available


  254. KIM HJ, Oh SH, Kim DY, Lee HS, et al
    Clinical Characteristics and Long-Term Outcomes of Paediatric Crohn's Disease: A Single-Centre Experience.
    J Crohns Colitis. 2017;11:157-164.
    PubMed     Text format     Abstract available


  255. VIRTA LJ, Saarinen MM, Kolho KL
    Inflammatory Bowel Disease Incidence is on the Continuous Rise Among All Paediatric Patients Except for the Very Young: A Nationwide Registry-based Study on 28-Year Follow-up.
    J Crohns Colitis. 2017;11:150-156.
    PubMed     Text format     Abstract available


  256. LIGHTNER AL, Raffals LE, Mathis KL, Cima RR, et al
    Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:185-190.
    PubMed     Text format     Abstract available


  257. WILLIET N, Sarter H, Gower-Rousseau C, Adrianjafy C, et al
    Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2017;11:165-174.
    PubMed     Text format     Abstract available


  258. HART AL, Lomer M, Verjee A, Kemp K, et al
    What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance.
    J Crohns Colitis. 2017;11:204-211.
    PubMed     Text format     Abstract available


  259. JAIRATH V, Levesque BG, Vande Casteele N, Khanna R, et al
    Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.
    J Crohns Colitis. 2017;11:246-255.
    PubMed     Text format     Abstract available


  260. SUZUKI K, Yokoyama J, Kawauchi Y, Honda Y, et al
    Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions.
    J Crohns Colitis. 2017;11:221-228.
    PubMed     Text format     Abstract available


  261. DEVRIESE S, Eeckhaut V, Geirnaert A, Van den Bossche L, et al
    Reduced Mucosa-associated Butyricicoccus Activity in Patients with Ulcerative Colitis Correlates with Aberrant Claudin-1 Expression.
    J Crohns Colitis. 2017;11:229-236.
    PubMed     Text format     Abstract available


  262. WRIGHT EK, Kamm MA, Wagner J, Teo SM, et al
    Microbial Factors Associated with Postoperative Crohn's Disease Recurrence.
    J Crohns Colitis. 2017;11:191-203.
    PubMed     Text format     Abstract available


  263. LEMMENS B, de Buck van Overstraeten A, Arijs I, Sagaert X, et al
    Submucosal Plexitis as a Predictive Factor for Postoperative Endoscopic Recurrence in Patients with Crohn's Disease Undergoing a Resection with Ileocolonic Anastomosis: Results from a Prospective Single-centre Study.
    J Crohns Colitis. 2017;11:212-220.
    PubMed     Text format     Abstract available


  264. KATSANOS KH, Domenech E, Rahier JF, Kopylov U, et al
    Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics.
    J Crohns Colitis. 2017;11:256-257.
    PubMed     Text format    


  265. WONG DR, Coenen MJ, Vermeulen SH, Derijks LJ, et al
    Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:175-184.
    PubMed     Text format     Abstract available


    January 2017
  266. HARBORD M, Eliakim R, Bettenworth D, Karmiris K, et al
    Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    J Crohns Colitis. 2017 Jan 28. doi: 10.1093.
    PubMed     Text format    


  267. RAZANSKAITE V, Bettey M, Downey L, Wright J, et al
    Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    J Crohns Colitis. 2017 Jan 27. pii: jjw216. doi: 10.1093.
    PubMed     Text format     Abstract available


  268. DANESE S, Fiorino G, Raine T, Ferrante M, et al
    ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    J Crohns Colitis. 2017;11:26-34.
    PubMed     Text format    


  269. SHINZAKI S, Matsuoka K, Iijima H, Mizuno S, et al
    Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:84-91.
    PubMed     Text format     Abstract available


  270. GOMOLLON F, Dignass A, Annese V, Tilg H, et al
    3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
    J Crohns Colitis. 2017;11:3-25.
    PubMed     Text format     Abstract available


  271. DETREZ I, Gils A
    Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    J Crohns Colitis. 2017;11:1-2.
    PubMed     Text format    


  272. PEYRIN-BIROULET L, Lonnfors S, Roblin X, Danese S, et al
    Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
    J Crohns Colitis. 2017;11:128-133.
    PubMed     Text format     Abstract available


  273. ROBBINS L, Zaghiyan K, Melmed G, Vasiliauskas E, et al
    Outcomes with Anti-Tumour Necrosis Factor-Alpha Therapy and Serology in Patients with Denovo Crohn's Disease After Ileal Pouch Anal Anastomosis.
    J Crohns Colitis. 2017;11:77-83.
    PubMed     Text format     Abstract available


  274. ADEDOKUN OJ, Xu Z, Marano CW, Strauss R, et al
    Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    J Crohns Colitis. 2017;11:35-46.
    PubMed     Text format     Abstract available


  275. SIMON M, Cosnes J, Gornet JM, Seksik P, et al
    Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn's Disease: A Prospective Cohort-Study in High-Risk Patients.
    J Crohns Colitis. 2017;11:47-52.
    PubMed     Text format     Abstract available


  276. PAPAMICHAEL K, Baert F, Tops S, Assche GV, et al
    Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
    J Crohns Colitis. 2017;11:53-59.
    PubMed     Text format     Abstract available


  277. HERNANZ N, Lopez-Sanroman A
    A Pitfall to Avoid: Hyperlipasemia, Azathioprine, and Autoimmune Pancreatitis.
    J Crohns Colitis. 2017;11:134.
    PubMed     Text format    


  278. HOOPER KM, Barlow PG, Stevens C, Henderson P, et al
    Inflammatory Bowel Disease Drugs: A Focus on Autophagy.
    J Crohns Colitis. 2017;11:118-127.
    PubMed     Text format     Abstract available


  279. CHEN W, Lu C, Hirota C, Iacucci M, et al
    Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme.
    J Crohns Colitis. 2017;11:92-104.
    PubMed     Text format     Abstract available


  280. KAMMERMEIER J, Dziubak R, Pescarin M, Drury S, et al
    Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
    J Crohns Colitis. 2017;11:60-69.
    PubMed     Text format     Abstract available


  281. JOSHI NM, Marks IH, Crowson R, Ball D, et al
    Incidence and Outcome of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease in the UK.
    J Crohns Colitis. 2017;11:70-76.
    PubMed     Text format     Abstract available


    November 2016
  282. EBERHARDSON M, Karlen P, Linton L, Jones P, et al
    Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
    J Crohns Colitis. 2016 Nov 2. doi: 10.1093.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: